AstraZeneca to Build Qingdao Regional Headquarters with Rare Disease Innovation Center
publication date: Jun 23, 2022
AstraZeneca will set up its sixth China regional headquarters in Qingdao, a port city in eastern Shandong province, forming a rare disease innovation center, a life science innovation park and an industry fund. The company will also construct a manufacturing facility for Breztri, an aerosol therapy for COPD at the site. AstraZeneca’s budesonide/glycopyrronium/formoterol fumarate COPD therapy was approved for China use in 2020 and added to China’s national medical insurance list last year. The company did not disclose any financial data for the expansion. More details....
Stock Symbol: (NYSE: AZN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.